Precision BioSciences(DTIL) - 2024 Q2 - Quarterly Results

Exhibit 99.1 Precision BioSciences Reports Second Quarter 2024 Financial Results and Provides Business Update - Wholly owned programs PBGENE-HBV for Chronic Hepatitis B virus and PBGENE-PMM for m.3243 mitochondrial disease on track for IND and/or CTA submissions in 2024 and 2025, respectively - Expanded Hepatitis Scientific Advisory Board with addition of world-class clinical investigators Mark Sulkowski, M.D. and Jordan Feld, M.D., M.P.H. - Sufficient capital to realize Phase 1 clinical data for multiple i ...